Abstract: The invention is a method for treating patients with cancer comprising administering to the patient a safe and effective dose of (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-hydroxyphenyl)acetamideor a pharmaceutically acceptable salt or hydrate thereof, wherein the dose is between about 40 mg once per per day and about 120 mg once per per day. In one embodiment of the invention, the dose is about 40 mg once per per day, about 80 mg once per day or about 120 mg once per per day. In another embodiment of the invention, the dose is about 40 mg once per day. In another embodiment of the invention, the dose is about 80 mg once per day. In another embodiment of the invention, the dose is about 120 mg once per day. In another embodiment of the invention, the cancer is acute leukemia, older adult hematologic malignancy, lymphoma or multiple myeloma. In another embodiment of the invention, the lymphoma is diffuse large B-cell lymphoma.

Abstract: Disclosed herein are compositions comprising a galectin-1-targeting compound in a therapeutically effective composition for treating cancer. In an aspect, a galectin-1-targeting compound is OTX-008. Also disclosed herein are methods of making and using such compositions.

Abstract: The present invention relates to the identification of various prognostic factors that predict response in patients with hyperproliferative disease such as cancer to gene therapy, and their use in methods of treating such patients with an anti-hyperproliferative disease gene therapy. Also described are methods of treatment for Li Fraumeni syndrome, and for assessing anti-cancer gene therapy using PET scans.